Officials give final OK to limit state health plan spending on Ozempic, Jardiance

During a virtual meeting Monday, PDAB member Dr. Georges Benjamin oversaw the vote that finalized new regulations capping how much state and local governments will pay for two prescription drugs on state health plans. (Photo by Danielle J. Brown/Maryland Matters)
State officials gave final approval Monday to regulations that cap how much state and local governments are willing to pay for two high-cost drugs by setting “upper payment limits” on treatments for type-2 diabetes and other conditions.
The Prescription Drug Affordability Board action set payment limits on two prescription drugs covered by state healthcare plans: Jardiance, a brand name for the drug empagliflozin, and Ozempic, a name brand for semaglutide.
The vote finalizes language that now goes to the state register for final evaluation. If no problems arise there, the new regulations would go into effect on Jan. 1, 2027, marking the first time the board has limited spending on high cost drugs since it was created in 2019.
“This landmark move will save state and local government millions of dollars,” Vincent DeMarco, president of the Medicare Healthcare for All coalition, said during public comments ahead of the board votes Monday.
Jardiance and Ozempic are both used to treat Type-2 diabetes among other conditions. Ozempic has also gained new attention for its use as a weight-loss drug. Healthcare advocates estimate that state and local governments could save around $6.1 million with upper payment limits set for those two drugs.
That may be a fraction of the $3 billion budget shortfall state lawmakers will likely need to address in the 2027 legislative session, but DeMarco called Monday’s vote is a “critically important step,” more possible savings on the horizon.
Board votes to cap how much state, local governments spend on Ozempic
It the upper payment limits take effect on Jan. 1, it would also start the clock on a possible expansion of the board’s authority from just state health plans to the private insurance market in 2028. A 2025 law authorized the expansion, but delayed it until one year after upper payment limits were set on two prescription drugs under its current authority.
Savings would increase significantly if the board’s authority expanded to reach private insurance, according to an analysis from Steve Ports Consulting, commissioned by Maryland Health Care for All.
That analysis said the expected $320,000 in Jardiance savings for state health plans could balloon to between $9 million and $16 million a year if expanded out to all Maryland health plans. Projected Ozempic savings would go from $5.8 million a year to somewhere between $113 million and $165 million a year.
Certain patient advocacy groups for people with chronic or rare diseases worry that upper payment limits will risk their ability to access their medications. And drug manufacturers warn that actions taken by the board may not result in out-of-pocket savings for patients at the pharmacy counter.
“These policies can introduce new incentives for insurers and pharmacy benefit managers (PBMs) that may ultimately restrict access to needed treatments through greater utilization management, formulary reshuffling, or adverse tiering,” according to a written comment to the board by the EACH/PIC coalition, a group of almost two dozen patient-advocacy groups for specific conditions.
“These shifts risk delaying or disrupting care, and … insurance barriers, not price alone, are often the real drivers of patient hardship and perceived ‘unaffordability,’” the statement said.
Advocates ‘thrilled’ by state decision to cap spending on diabetes drug Jardiance
State officials respond by saying that upper payment limits are not expected to limit access, but if they do, the board can alter the policy to address the issue.
Meanwhile, other healthcare advocates say expanding the board’s authority to the private market will result in even more savings that could free up state and local funds to go toward other healthcare programs.
“Beyond reducing costs, these measures could expand access to lifesaving medications,” said Sara Westrick, AARP Maryland’s advocacy director, said in a written comment to the board. “Greater affordability may also allow more patients to start treatment and continue taking their prescribed medications, thereby improving adherence and potentially increasing appropriate utilization.”
DeMarco is also leading the charge on proposed 2027 legislation that would let the board more easily set upper payment limits for prescription drugs based on the Maximum Fair Price, which is negotiated between federal officials and pharmaceutical companies to offer lower prescription drug costs for those on Medicare.
Advocates claim that could yield over $665 million in savings on the 25 drugs already negotiated under the Maximum Fair Price policy, with additional savings added as federal officials continue to negotiate lower prices for other medications covered by Medicare.
Ver nota original ↗
¿Querés un resumen rápido de esta noticia, hecho por nuestra IA?
